Carlos Galamba
With more than 18 years of experience in the IVD sector, including hands-on work as a scientist in transfusion medicine and infectious disease diagnostics, and regulatory review experience at BSI, one of the EU's largest Notified Bodies, Carlos Galamba brings a uniquely integrated perspective to IVD regulatory strategy. Their work spans Class C/D IVDs, companion diagnostics, NGS-based assays, and software-based IVDs, with a current advisory role to the European Commission on regulatory matters. At MDx CRO, they lead regulatory strategy for complex IVD programs across EU IVDR, FDA, and global markets.
Latest Articles
Blog & Insights
IMDRF Draft N91 2026: New Clinical Evidence Requirements for IVDs Explained
Last Updated: 2026-07-14
Read more
Blog & Insights
The IVDR CDx Certification Pathway: From Notified Body to EMA Opinion
Last Updated: 2026-08-10
Read more
IVD News
ISO 20916:2024 What You Need to Know for Clinical Performance Studies in 2026
The 2024 revision of ISO 20916, now published as EN ISO 20916:2024, marks a major step forward in…
Last Updated: 2026-07-14
Read more
Blog & Insights
Blog & Insights
MDR and IVDR Targeted Revision
If you build, launch, or maintain medical devices or IVDs in the EU, the MDR/IVDR targeted revision is…
Last Updated: 2026-07-15
Read more
Regulatory Updates
Impact of the Health Services Pack on IVD manufacturers, labs/health institutions and sponsors of combined studies
The Health Services Pack proposal introduces potential IVDR changes affecting IVD manufacturers, labs, and combined-study sponsors. This article…
Last Updated: 2026-07-15
Read more
IVD News
FDA’s New CDx Pathway vs EU IVDR: Harmonised Science, Diverging Workload
Last Updated: 2026-08-10
Read more
IVD News
FDA Proposes to Down‑Classify Key Oncology Companion Diagnostics to Class II: What CDx Sponsors Need to Know
FDA proposes reclassifying many nucleic acid‑based oncology companion diagnostics, here’s what CDx sponsors need to know.
Last Updated: 2026-07-15
Read more